The Global Health Body Sounds Alert Over Severe Shortage of Obesity Injections

Fewer than one in 10 people that would benefit from weight-loss injections such as Wegovy are able to get them, states the WHO as it releases its inaugural recommendations on the drugs.

Given over a billion individuals worldwide currently classified as obese, it is advocating for increased and just availability to GLP-1 medication.

According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.

"Our latest guidance recognises that obesity is a long-term condition that can be treated with thorough and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and distribution challenges are major obstacles to universal availability to the treatments that can help people shift considerable weight, explains the body.

Weight-Loss Drug Scarcity

Despite the present best projected scenario, the manufacturing of such drugs would only suffice for approximately 100 million people – fewer than 10% of eligible patients, according to the health organization.

The advice encourages nations and manufacturers to increase availability, by approaches like voluntary licensing.

A patent on semaglutide – the main component of the drug Wegovy – is scheduled to end in multiple nations in 2026.

The Way Weight-Loss Injections Operate

GLP-1 drugs imitate a biological compound to delay gastric emptying, curb appetite and enhance feelings of fullness so users consume fewer calories.

People typically see weight reduction within a few weeks of starting on the once-weekly jabs.

Studies points to people may regain a significant portion after a year of stopping the medication, because their normal hunger come back.

Being overweight or obese increases your risk for contracting diseases, such as diabetes, heart disease, stroke, and specific cancers.

Obesity affects people in every country and was responsible for over three and a half million deaths worldwide in 2024, as per the health agency.